These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 19487300)

  • 1. Adaptive therapy.
    Gatenby RA; Silva AS; Gillies RJ; Frieden BR
    Cancer Res; 2009 Jun; 69(11):4894-903. PubMed ID: 19487300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
    Ibrahim-Hashim A; Robertson-Tessi M; Enriquez-Navas PM; Damaghi M; Balagurunathan Y; Wojtkowiak JW; Russell S; Yoonseok K; Lloyd MC; Bui MM; Brown JS; Anderson ARA; Gillies RJ; Gatenby RA
    Cancer Res; 2017 May; 77(9):2242-2254. PubMed ID: 28249898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A theoretical quantitative model for evolution of cancer chemotherapy resistance.
    Silva AS; Gatenby RA
    Biol Direct; 2010 Apr; 5():25. PubMed ID: 20406443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
    Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
    Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.
    Hamis S; Nithiarasu P; Powathil GG
    J Theor Biol; 2018 Oct; 454():253-267. PubMed ID: 29909142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage strategies for delaying resistance emergence in heterogeneous tumors.
    Vakil V; Trappe W
    FEBS Open Bio; 2021 May; 11(5):1322-1331. PubMed ID: 33638275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
    Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
    Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?
    Ledzewicz U; Schättler H
    Cancer Lett; 2017 Aug; 401():74-80. PubMed ID: 28323033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
    Cho H; Levy D
    J Theor Biol; 2018 Jan; 436():120-134. PubMed ID: 29030212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
    Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
    Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
    Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolutionary analysis of replicator dynamics about anti-cancer combination therapy.
    Zhao R; Lai X
    Math Biosci Eng; 2023 Jan; 20(1):656-682. PubMed ID: 36650783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards Multidrug Adaptive Therapy.
    West J; You L; Zhang J; Gatenby RA; Brown JS; Newton PK; Anderson ARA
    Cancer Res; 2020 Apr; 80(7):1578-1589. PubMed ID: 31948939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolutionary approaches to prolong progression-free survival in breast cancer.
    Silva AS; Kam Y; Khin ZP; Minton SE; Gillies RJ; Gatenby RA
    Cancer Res; 2012 Dec; 72(24):6362-70. PubMed ID: 23066036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
    Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer.
    Brown JS; Cunningham JJ; Gatenby RA
    IEEE Trans Biomed Eng; 2017 Mar; 64(3):512-518. PubMed ID: 28113286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of synergy and antagonism in designing multidrug adaptive chemotherapy schedules.
    Ma Y; Newton PK
    Phys Rev E; 2021 Mar; 103(3-1):032408. PubMed ID: 33862722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.